Chris Garabedian

Chris Garabedian is a seasoned executive in the healthcare sector, currently serving as Portfolio Manager for the PXV Fund at Perceptive Advisors since May 2017. Garabedian holds multiple leadership roles, including Chairman and CEO of Xontogeny, and Board Member positions at several companies such as CereVasc, Zucara Therapeutics Inc., and AsclepiX Therapeutics, Inc. Notably, Garabedian previously served as Chairman of the Board at Landos Biopharma, Inc. and Forge Biologics, as well as Chief Executive Officer at Sarepta Therapeutics from January 2011 to March 2015. Garabedian also contributed to the Boston Consulting Group as a Senior Advisor to the Healthcare Practice from January 2016 to December 2021. Garabedian earned a B.S. in Marketing from the University of Maryland from 1985 to 1989.